ArticleGut2021
Mass eradication of
Article in Gut, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 135 papers, 7 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Community-based Helicobacter Pylori Eradication With Two Sequential Antibiotic Regimens for the Residents and Migrants From a High-risk Area for Gastric Cancer
Optimized Bismuth Quadruple Therapy vs Triple Standard Therapy for Helicobacter Pylori Eradication: Clinical Efficacy Randomized Trial
EU4Health Project Eurohelican: A Single-center Prospective Feasibility Study of the Proposed Test-and-treat Preventive Screening Program in Younger Slovenian Participants Aged 30-34 Years With or Without Helicobacter Pylori Infection
Who cites it
135 citing papers in PubMed, 7 syntheses or guidelines pooled it.
- Asian Pacific Association of Gastroenterology task force recommendations on surveillance forGut · 2026Guideline
- First regional consensus on the management ofWorld journal of gastroenterology · 2025Guideline
- ACG Clinical Guideline: Diagnosis and Management of Gastric Premalignant Conditions.The American journal of gastroenterology · 2025Guideline
- Prevalence ofWorld journal of gastroenterology · 2024Pooled it
- Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with gastric cancer.ESMO open · 2024Guideline
- Effectiveness of eradication therapy for Helicobacter pylori infection in Africa: a systematic review and meta-analysis.BMC gastroenterology · 2023Pooled it
- Survival of gastric cancer in China from 2000 to 2022: A nationwide systematic review of hospital-based studies.Journal of global health · 2022Pooled it
- Comparison of Keverprazan-based versus esomeprazole-based dual therapy for initial treatment ofAnnals of medicine · 2026Trial
- Trial
- Screening for Helicobacter pylori to Prevent Gastric Cancer: A Pragmatic Randomized Clinical Trial.JAMA · 2024Trial
- Gastric cancer prevention by community eradication of Helicobacter pylori: a cluster-randomized controlled trial.Nature medicine · 2024Trial
- Bismuth-Containing Quadruple Therapy for Helicobacter pylori Eradication: A Randomized Clinical Trial of 10 and 14 Days.Digestive diseases and sciences · 2024Trial
- Safety and effectiveness of vonoprazan-based rescue therapy forWorld journal of gastroenterology · 2023Trial
- Enhanced COMP expression induced by Helicobacter pylori drives gastric cancer progression by NOTCH2/SMAD3 pathway.Journal of gastroenterology · 2026Article
- Gastric Intestinal Metaplasia After Helicobacter pylori Eradication: Reframing the Reversibility Controversy.Digestive diseases and sciences · 2026Review
- Genetically determined heterogeneous treatment effects ofInnovation (Cambridge (Mass.)) · 2026Article
- Nativity as a Clinical Variable in Gastric Cancer Prevention: An Immigrant Health Perspective.Journal of immigrant and minority health · 2026Review
- AdolescentChildren (Basel, Switzerland) · 2026Review
- Trends inThe Lancet regional health. Western Pacific · 2026Article
- Bad bugs mean business: gastric cancer is an intended consequence ofInfection and immunity · 2026Review
75 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveAlthough mass eradication of
designMass eradication of
resultsAfter six rounds of mass screening and eradication, the coverage rate reached 85.5% (6512/7616). The referral rate for treatment was 93.5% (4286/4584). The prevalence rates of
conclusionPopulation-based eradication of TRIAL REGISTRATION NUMBER: NCT00155389.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.